News

Skin care for diabetes management focuses on prevention, routine inspections, and maintaining healthy skin to avoid complications.

Discover the promising efficacy and safety of combining platelet-rich plasma with fractional laser therapy for treating vitiligo in adults.

Celltrion's Yuflyma gains full FDA interchangeability, enhancing patient access and affordability for various inflammatory conditions.

As melanoma rates rise, Victor Gall, MD, emphasizes proactive care, early detection, and innovative treatments to improve patient outcomes and survival rates.

A melanoma survivor shares her journey, emphasizing the importance of early detection and regular skin exams for skin cancer awareness.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA clearance for a pivotal trial to assess its effectiveness and safety.

A recent analysis reveals safety profiles of apremilast and deucravacitinib for psoriasis, highlighting unique adverse events and long-term monitoring needs.

Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearance for a phase 1 trial for mild to moderate psoriasis.

Researchers reveal the resilience of Cutibacterium acnes in the skin microbiome post-laser treatments, suggesting its beneficial roles in skin health and aging.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tralokinumab offers a promising alternative for patients with atopic dermatitis experiencing dupilumab-related arthralgia, achieving skin clearance and symptom relief.

A recent study reveals that combining topical anti-aging products with Thermage enhances skin hydration and reduces fine lines for lasting results.

Triveni Bio initiates a phase 1 trial for TRIV-509, a promising treatment for atopic dermatitis, targeting key inflammatory pathways.

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

A 10-year study reveals azathioprine's impressive 93% hair regrowth rate in patients with moderate to severe alopecia, highlighting its long-term efficacy and safety.

Explore how AI, particularly ChatGPT, impacts dermatology education, revealing strengths and limitations in clinical decision-making and training.

This review of the latest dermatologic studies includes insights into chronic hand eczema, including self-reported severity, burden of pain and use of analgesics, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Four variations of virucidal sanitizers were evaluated for their effect on skin irritation, erythema, transepidermal water loss, and more.

Discover how Shaant ClearSkin Probiotic offers a holistic approach to acne treatment by targeting gut health and hormonal balance for clearer skin.

New research explores how microgravity and cosmic radiation influence cancer cell behavior, immune responses, and potential advancements in oncology treatments.

Explore the evolving landscape of self-reported hand eczema severity assessments, highlighting their potential and challenges in clinical research and digital health.

Julia Zimmermann, PD, PHD's innovative cold plasma technology for acne treatment, developed through extensive research, promises effective results for clearer skin.

A melanoma survivor shares her journey, emphasizing the importance of sun safety and regular skin exams to prevent skin cancer.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.

A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.